RA
ACH

Royce & Associates’s Accendra Health ACH Stock Holding History

Royce & Associates’s Portfolio ACH Stock Details ACH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,698
Closed -$58.6K – 809
2026
Q1 		$58.6K Sell
25,698
-42,451
-62% -$97.8K ﹤0.01% 769
2025
Q4 		$191K Sell
68,149
-19,345
-22% -$69.1K ﹤0.01% 746
2025
Q3 		$420K Sell
87,494
-8,280
-9% -$52.7K ﹤0.01% 717
2025
Q2 		$872K Buy
95,774
+5,852
+7% +$43.1K 0.01% 678
2025
Q1 		$812K Hold
89,922
– – 0.01% 695
2024
Q4 		$1.18M Buy
89,922
+9,008
+11% +$120K 0.01% 703
2024
Q3 		$1.27M Buy
80,914
+51,955
+179% +$787K 0.01% 695
2024
Q2 		$391K Buy
+28,959
New +$593K ﹤0.01% 807
2022
Q3 		– Sell
-103,124
Closed -$3.24M – 959
2022
Q2 		$3.24M Sell
103,124
-143,000
-58% -$5.18M 0.03% 582
2022
Q1 		$10.8M Sell
246,124
-186,000
-43% -$7.99M 0.09% 330
2021
Q4 		$18.8M Sell
432,124
-47,000
-10% -$1.84M 0.14% 216
2021
Q3 		$15M Sell
479,124
-238,026
-33% -$9.37M 0.11% 291
2021
Q2 		$30.4M Sell
717,150
-264,400
-27% -$10.3M 0.21% 138
2021
Q1 		$36.9M Buy
981,550
+130,429
+15% +$4.08M 0.25% 101
2020
Q4 		$23M Sell
851,121
-44,496
-5% -$1.14M 0.19% 147
2020
Q3 		$22.5M Sell
895,617
-1,025,391
-53% -$15M 0.24% 103
2020
Q2 		$14.6M Sell
1,921,008
-130,000
-6% -$951K 0.16% 171
2020
Q1 		$18.8M Sell
2,051,008
-83,477
-4% -$504K 0.26% 98
2019
Q4 		$11M Buy
2,134,485
+122,653
+6% +$788K 0.1% 296
2019
Q3 		$11.7M Buy
2,011,832
+121,046
+6% +$543K 0.11% 265
2019
Q2 		$6.05M Buy
1,890,786
+535,000
+39% +$1.82M 0.05% 448
2019
Q1 		$5.56M Buy
1,355,786
+190,000
+16% +$1.2M 0.05% 484
2018
Q4 		$7.38M Buy
1,165,786
+351,000
+43% +$3.64M 0.07% 409
2018
Q3 		$13.5M Buy
814,786
+217,000
+36% +$3.69M 0.09% 329
2018
Q2 		$9.99M Sell
597,786
-138,800
-19% -$2.25M 0.07% 393
2018
Q1 		$11.5M Sell
736,586
-22,800
-3% -$407K 0.08% 346
2017
Q4 		$14.3M Buy
759,386
+443,316
+140% +$9.83M 0.1% 299
2017
Q3 		$9.23M Sell
316,070
-412,600
-57% -$12.2M 0.06% 405
2017
Q2 		$23.5M Sell
728,670
-32,000
-4% -$1.05M 0.16% 187
2017
Q1 		$26.3M Buy
760,670
+43,000
+6% +$1.54M 0.17% 161
2016
Q4 		$25.3M Buy
717,670
+18,670
+3% +$631K 0.16% 175
2016
Q3 		$24.3M Sell
699,000
-171,350
-20% -$6M 0.16% 174
2016
Q2 		$32.5M Sell
870,350
-278,300
-24% -$10.5M 0.22% 136
2016
Q1 		$46.4M Sell
1,148,650
-77,500
-6% -$2.89M 0.29% 92
2015
Q4 		$44.1M Sell
1,226,150
-146,000
-11% -$5.28M 0.26% 100
2015
Q3 		$43.8M Sell
1,372,150
-103,000
-7% -$3.51M 0.23% 118
2015
Q2 		$50.2M Sell
1,475,150
-119,100
-7% -$4.01M 0.21% 122
2015
Q1 		$53.9M Sell
1,594,250
-88,800
-5% -$3.09M 0.2% 128
2014
Q4 		$59.1M Sell
1,683,050
-766,994
-31% -$25.8M 0.21% 130
2014
Q3 		$80.2M Buy
2,450,044
+144,100
+6% +$4.9M 0.27% 92
2014
Q2 		$78.4M Buy
2,305,944
+243,500
+12% +$8.34M 0.23% 109
2014
Q1 		$72.2M Buy
2,062,444
+231,894
+13% +$8.18M 0.21% 123
2013
Q4 		$66.9M Hold
1,830,550
– – 0.19% 143
2013
Q3 		$63.3M Hold
1,830,550
– – 0.19% 134
2013
Q2 		$61.9M Buy
+1,830,550
New +$60.8M 0.19% 130

Other funds holding ACH

CCM
Coliseum Capital Management Rowayton, Connecticut $1.16B AUM 23.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Royce & Associates's ACH Position: Q2 2026 in Review

Royce & Associates sold out of Accendra Health (ACH) in Q2 2026, closing a stake of 25,698 shares — an estimated $58.6K sold.

Royce & Associates first reported a position in ACH in Q2 2013 and held it in 45 quarters. The position peaked at $80.2M in Q3 2014. 139 funds tracked by Wall St. Rank hold ACH as of Q2 2026.

  • Royce & Associates reported no remaining Accendra Health position as of Q2 2026 after selling out during the quarter.
  • Royce & Associates sold 25,698 Accendra Health shares in Q2 2026, an estimated $58.6K.
  • Royce & Associates first reported a position in Accendra Health in Q2 2013 and held it in 45 quarters.
  • Royce & Associates's Accendra Health position peaked at $80.2M in Q3 2014.
  • 139 funds tracked by Wall St. Rank held Accendra Health as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.